260. Trends in Susceptibility of Tigecycline against Selected Gram-Negative European Pathogens (TEST 2004 – 2010)
Session: Poster Abstract Session: Antimicrobial Susceptibility and Resistance
Friday, October 21, 2011
Room: Poster Hall B1

Background: The Tigecycline Evaluation and Surveillance Trial (TEST) monitors the activity of tigecycline and comparators against multiple pathogens collected worldwide. Such monitoring assists in investigating resistance rates either globally, regionally or by country. The current report describes trends in tigecycline susceptibility of commonly isolated gram-negative pathogens between 2004 and 2010.

Methods:    A total of 33,988 clinical isolates were collected from multiple infection sources in Europe between 2004 and 2010. Susceptibility testing was performed as per CLSI guidelines and interpreted using EUCAST clinical breakpoints. Linear trends in percent susceptible were assessed with the Cochran-Armitage test for trend.

Results:   Susceptibility to tigecycline of the 5,285 gram-negative isolates collected in 2004 and 2010 is reported below. Although % susceptible is only shown for 2004 and 2010, trends in susceptibility were assessed using all years from 2004 to 2010.

* Statistically significant decrease in susceptibility; ** Statistically significant increase in susceptibility (p<0.05).

Conclusion:   Susceptibility data show that from 2004 to 2010 susceptibility of the selected species remained remarkably stable. Only E. coli and S. marcescens showed slight, but statistically significant decreases in % susceptible (from 99.7 to 98.2% and 84.6 to 80.0%, respectively) over the seven-year period, while ESBL-positive K. pneumoniae isolates showed a slight increase in susceptibility (p<0.05). While susceptibility has remained relatively stable, further susceptibility monitoring over time is warranted.

 


Subject Category: A. Antimicrobial agents and Resistance

Stephen Hawser, PhD1, Samuel Bouchillon, MD2, Robert Badal, BS2, Jack Johnson, MS, MBA2 and Michael Dowzicky, MS3, (1)IHMA Europe Sŕrl, Epalinges, Switzerland, (2)IHMA, Inc., Schaumburg, IL, (3)Pfizer, Inc., Collegeville, PA

Disclosures:

S. Hawser, Pfizer, Inc.: Consultant, Consulting fee

S. Bouchillon, Pfizer, Inc.: Consultant, Consulting fee

R. Badal, Pfizer, Inc.: Consultant, Consulting fee

J. Johnson, Pfizer, Inc.: Consultant, Consulting fee

M. Dowzicky, Pfizer, Inc.: Employee, Salary

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.